The FDA's all-oral AML approval changes where care happens. Thursday's brief named Inqovi plus venetoclax as the first all-oral combination for newly diagnosed acute myeloid leukemia patients who are at least 75 or ineligible for intensive induction chemotherapy.

FDA approved the combination of oral decitabine and cedazuridine tablets with venetoclax on May 13. [1] Taiho's release framed it as a first for this patient population and a way to reduce the burden of parenteral treatment. [2]

That is true, but incomplete. An oral regimen does not make cancer care simple. It moves work from the infusion chair to the kitchen table: pill timing, missed-dose anxiety, infection monitoring, lab visits, caregiver supervision and the discipline of calling before a fever becomes a crisis.

For older AML patients, fewer clinic days are not cosmetic. Travel, fatigue and infection exposure are clinical facts. But a home regimen also means the system has to see the patient when the patient is not physically in the system. The approval is a convenience story only if the monitoring plan follows the pills home.

That is why the kitchen table belongs in the approval story alongside the trial table, the label, and the clinic calendar.

-- NORA WHITFIELD, Chicago